Dideoxyadenosine

A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.

Also Known As:

Networked: 14 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Han, Lina: 1 article (07/2012)
2.	Wang, Ben: 1 article (07/2012)
3.	Yu, Yerong: 1 article (07/2012)
4.	Esumi, Mariko: 1 article (08/2008)
5.	Kitajima, Akiko: 1 article (08/2008)
6.	Mochida, Jun'ichi: 1 article (08/2008)
7.	Okada, Kiyoki: 1 article (08/2008)

Related Diseases

1.	Acquired Immunodeficiency Syndrome (AIDS) 04/01/1990 - "In this report, we have compared the uptake, metabolism, and relevant enzymology of a novel anti-acquired immunodeficiency syndrome drug, 2'-fluoro-2',3'-dideoxyarabinosyladenine (2'-F-dd-ara-A) with the corresponding properties of its parent compound 2',3'-dideoxyadenosine (2',3'-ddAdo) in three human T cell lines, MOLT-4, ATH8, and CEM. " 08/01/1992 - "A high-performance liquid chromatographic method with precolumn fluorescence derivatization using 2-(5-chlorocarbonyl-2-oxazolyl)-5,6-methylenedioxybenzofu ran is described for the quantification of 2',3'-dideoxyinosine, a therapeutic drug for acquired immunodeficiency syndrome, and 2',3'-dideoxyadenosine, an anti-human-immunodeficiency-viral agent, in rat plasma. " 05/01/1990 - "This article describes the pharmacokinetics of 2',3'-dideoxyadenosine (ddA) and 2',3'-dideoxyinosine (ddI) as determined during phase I clinical trials in patients with acquired immunodeficiency syndrome and acquired immunodeficiency syndrome-related complex. " 09/15/1990 - "2',3'-Dideoxyadenosine (ddA) is a nucleoside analogue with anti-HIV activity and one of its metabolic products, 2',3'-dideoxyinosine (ddI), has shown promising results in clinical trials for the treatment of acquired immunodeficiency syndrome (AIDS). " 04/01/1987 - "We report that 2',3'-dideoxyadenosine and 2',3'-dideoxycytidine inhibit retroviral DNA synthesis and mRNA expression in T cells exposed to the virus that causes acquired immunodeficiency syndrome, and afford such cells long-term protection in vitro under conditions of substantial viral excess. "
2.	Infections 07/01/1989 - "However, introducing an inhibitor of virus replication, 2',3' dideoxyadenosine, after infection of the DC but before culturing with lymphocytes, blocked growth of HIV in lymphocytes. " 03/15/1988 - "2',3'-dideoxyadenosine (ddAdo) has been shown to inhibit the infection of cultured human T lymphoblasts with the human immunodeficiency virus-1 (HIV-1). " 03/01/1981 - "2',3'-Dideoxyadenosine (DDA) was shown not only to possess antibacterial activity in vitro against a variety of Enterobacteriaceae, but also to be effective in vivo, DDA was active in experimental mouse infections by the oral route against 5 Salmonella strains, 2 of 3 Arizona strains, 5 of 7 Citrobacter strains, 3 of 8 Klebsiella strains, 3 of 5 Escherichia strains, 1 of 3 Shigella strains, and 3 of 15 Serratia strains at concentrations generally well below the toxic level. " 05/01/1990 - "Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection."
3.	Simian Acquired Immunodeficiency Syndrome 10/01/1988 - "We tested the ability of 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxycytidine (ddC), and 2',3'-dideoxyadenosine (ddA) to inhibit the in vitro cytopathic effect (syncytium formation) and infectivity of the SAIDS-D/WA virus. " 10/01/1988 - "Antiviral effects of 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, and 2',3'-dideoxyadenosine against simian acquired immunodeficiency syndrome-associated type D retrovirus in vitro."
4.	Sarcoma 180 01/15/1988 - "The substrate specificity of trypanosomal MeSAdo/Ado phosphorylase differed from that of a mammalian MeSAdo phosphorylase (derived from murine Sarcoma 180 cells) in that it was able to phosphorolyze 2'-deoxyadenosine, 3'-deoxyadenosine and 2',3'-dideoxyadenosine. "
5.	Neoplasms (Cancer) 08/01/2008 - "Template directed incorporation of fluorescent dideoxyguanosine triphosphate or dideoxyadenosine triphosphate was quantitatively analyzed and the A/G (G/A) signal ratio was compared between tumor and nontumor tissues. "

Related Drugs and Biologics

1.	bis(p-chlorophenyl)acetic acid (DDA)
2.	Didanosine (Videx)
3.	Nucleosides
4.	Zalcitabine (Hivid)
5.	Adenylyl Cyclases (Adenylyl Cyclase)
6.	Adiponectin
7.	Zidovudine (Retrovir)
8.	Messenger RNA (mRNA)
9.	Phosphorylases (Glucan Phosphorylase)
10.	Colforsin